Abstract
BackgroundLiraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM). MethodsThrough March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty. ResultsFinally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P<0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages >1.6 mg/d and durations ≥24 weeks. Linear (P<0.001) and non-linear (P dose-response =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high. ConclusionsLRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
